Soleno Therapeutics, Inc. (SLNO) has been on a downward spiral lately with significant selling pressure. After declining 21.7 ...

Children were reportedly hospitalized after starting treatment. Scorpion Capital suggests Soleno's medication could face ...

H.C. Wainwright raised the firm’s price target on Soleno Therapeutics (SLNO) to $110 from $100 and keeps a Buy rating on the shares. The firm says ...

Soleno Therapeutics Inc (NASDAQ:SLNO) stock fell 13% Friday morning following a short report from Scorpion Capital that raised serious concerns about the company’s recently approved Prader-Willi ...

Scorpion Capital disclosed a short position in Soleno Therapeutics on Friday, citing issues with the drugmaker's recently approved treatment Vykat XR, sending its shares slumping 15% in premarket ...

SLNO is quite a good fit in this regard, gaining 52.3% over this period. However, it's not enough to look at the price change for around three months, as it doesn't reflect any trend reversal that ...

Shares of Soleno Therapeutics, Inc.(SLNO) have gained 2.2% over the past four weeks to close the last trading session at $86.02, but there could still be a solid upside left in the stock if short ...

Opportunity, LLC Vivo, a 10% owner of $SLNO, sold 1,100,000 shares of the company on 03-27-2025 for an estimated $74,580,000. We received data on the trade from a recent SEC filing.

Soleno Therapeutics (SLNO) is scheduled to report earnings on March 5, 2025. The last reported earnings were for reported on November 6, 2024 for Q3. Q ...